{
    "nct_id": "NCT05945875",
    "official_title": "Official Title Targeted Dual Modality Imaging (TDMI) for Detection and Removal of Head and Neck Cancer",
    "inclusion_criteria": "* Age >= 19 years\n* Biopsy-confirmed diagnosis of squamous cell carcinoma of the head and neck\n* Subjects diagnosed with any T stage, any subsite within the head and neck that are scheduled to undergo surgical resection and neck dissection. Subjects with recurrent disease or a new primary will be allowed\n* Planned standard of care elective neck dissection for a cN0 or node- positive disease. Clinical node- positive disease will be defined as metastasis in a single, ipsilateral lymph node, 3 cm or less in greatest dimension by clinical exam, cross sectional imaging or metabolic imaging\n* Hemoglobin >= 9 gm/dL\n* White blood cell count > 3000/mm^3\n* Platelet count >= 100,000/mm^3\n* Serum creatinine =< 1.5 times upper reference range\n* Ability to understand and the willingness to sign a written informed consent document\nHealthy volunteers allowed\nMust have minimum age of 19 Years",
    "exclusion_criteria": "* Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease; or unstable angina within 6 months prior to enrollment\n* Evidence of QT prolongation on pretreatment electrocardiogram (ECG) (greater than 440 ms in males or greater than 450 ms in females)\n* History of infusion reactions to monoclonal antibody therapies\n* History of allergies to iodine\n* Pregnant or breastfeeding\n* Magnesium or potassium lower than the normal institutional values\n* Subjects receiving class IA (quinidine, procainamide) or class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents\n* Subjects with a history or evidence of interstitial pneumonitis or pulmonary fibrosis\n* Severe renal disease or anuria\n* Thyroid stimulating hormone (TSH) > 13 micro international units/mL",
    "miscellaneous_criteria": ""
}